Mosunetuzumab, a CD20×CD3 BsAb, demonstrates activity in heavily pretreated FL including those with high-risk features and provides encouraging survival outcomes with Kaplan-Meier estimates for PFS (A) and OS (B) in the intent to treat population (n = 90).

Mosunetuzumab, a CD20×CD3 BsAb, demonstrates activity in heavily pretreated FL including those with high-risk features and provides encouraging survival outcomes with Kaplan-Meier estimates for PFS (A) and OS (B) in the intent to treat population (n = 90).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal